{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:14:12Z","timestamp":1794305652423,"version":"4.9.0"},"reference-count":219,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2017M622142"],"award-info":[{"award-number":["2017M622142"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Special Fund for Post-doctoral Innovative Projects in Shandong Province of China","award":["201703029"],"award-info":[{"award-number":["201703029"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is one of the most common causes of dementia. Its pathogenesis is characterized by the aggregation of the amyloid-\u03b2 (A\u03b2) protein in senile plaques and the hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Current medications for AD can provide temporary help with the memory symptoms and other cognitive changes of patients, however, they are not able to stop or reverse the progression of AD. New medication discovery and the development of a cure for AD is urgently in need. In this review, we summarized drugs for AD treatments and their recent updates, and discussed the potential of microglia induced neuroinflammation as a target for anti-AD drug development.<\/jats:p>","DOI":"10.3390\/ijms20030558","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T03:40:55Z","timestamp":1548733255000},"page":"558","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Drug Development for Alzheimer\u2019s Disease: Microglia Induced Neuroinflammation as a Target?"],"prefix":"10.3390","volume":"20","author":[{"given":"Yuan","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Medical College, Qingdao University, Qingdao 266071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoheng","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Cheng","sequence":"additional","affiliation":[{"name":"The Brain Science Center, Beijing Institute of Basic Medical Sciences, 100850 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical College, Qingdao University, Qingdao 266071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"b158","DOI":"10.1136\/bmj.b158","article-title":"Alzheimer\u2019s disease","volume":"338","author":"Burns","year":"2009","journal-title":"BMJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.arcmed.2012.11.009","article-title":"Early-onset Alzheimer\u2019s disease: Nonamnestic subtypes and type 2 AD","volume":"43","author":"Mendez","year":"2012","journal-title":"Arch. Med. Res."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association (2016). 2016 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc., 12, 459\u2013509.","DOI":"10.1016\/j.jalz.2016.03.001"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/CLEP.S37929","article-title":"Clinical epidemiology of Alzheimer\u2019s disease: Assessing sex and gender differences","volume":"6","author":"Mielke","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010-2050) estimated using the 2010 census","volume":"80","author":"Hebert","year":"2013","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2105\/AJPH.2014.301935","article-title":"Characterization of dementia and Alzheimer\u2019s disease in an older population: Updated incidence and life expectancy with and without dementia","volume":"105","author":"Tom","year":"2015","journal-title":"Am. J. Public Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.neurobiolaging.2007.05.017","article-title":"Menopausal transition: A possible risk factor for brain pathologic events","volume":"30","author":"Bonomo","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.yfrne.2009.04.015","article-title":"Protective actions of sex steroid hormones in Alzheimer\u2019s disease","volume":"30","author":"Pike","year":"2009","journal-title":"Front. Neuroendocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1124\/pr.111.005272","article-title":"Insights into rapid modulation of neuroplasticity by brain estrogens","volume":"65","author":"Srivastava","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S1474-4422(12)70191-6","article-title":"Cognitive reserve in ageing and Alzheimer\u2019s disease","volume":"11","author":"Stern","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.maturitas.2014.05.008","article-title":"Sex and gender differences in the causes of dementia: A narrative review","volume":"79","author":"Rocca","year":"2014","journal-title":"Maturitas"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0197-4580(98)00052-9","article-title":"Evolution in the conceptualization of dementia and Alzheimer\u2019s disease: Greco-Roman period to the 1960s","volume":"19","author":"Berchtold","year":"1998","journal-title":"Neurobiol. Aging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2013.03.030","article-title":"Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer\u2019s disease","volume":"153","author":"Zhang","year":"2013","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2174\/15680266113139990135","article-title":"The multifactorial nature of Alzheimer\u2019s disease for developing potential therapeutics","volume":"13","author":"Carreiras","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00401-009-0536-x","article-title":"Synaptic degeneration in Alzheimer\u2019s disease","volume":"118","author":"Arendt","year":"2009","journal-title":"Acta Neuropathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer\u2019s disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1086\/302553","article-title":"Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum","volume":"65","author":"Campion","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jama.2013.3507","article-title":"Genome-wide association studies, Alzheimer disease, and understudied populations","volume":"309","author":"Nussbaum","year":"2013","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer\u2019s disease","volume":"103","author":"Mahley","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaneurol.2017.2188","article-title":"Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis","volume":"74","author":"Neu","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1211103","article-title":"Variant of TREM2 associated with the risk of Alzheimer\u2019s disease","volume":"368","author":"Jonsson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer\u2019s disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Abduljaleel, Z., Al-Allaf, F.A., Khan, W., Athar, M., Shahzad, N., Taher, M.M., Elrobh, M., Alanazi, M.S., and El-Huneidi, W. (2014). Evidence of trem2 variant associated with triple risk of Alzheimer\u2019s disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092648"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1093\/hmg\/ddu277","article-title":"Coding variants in TREM2 increase risk for Alzheimer\u2019s disease","volume":"23","author":"Jin","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s10072-015-2274-2","article-title":"TREM2 variants and risk of Alzheimer\u2019s disease: A meta-analysis","volume":"36","author":"Lu","year":"2015","journal-title":"Neurol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.tins.2008.06.005","article-title":"Neuronal calcium mishandling and the pathogenesis of Alzheimer\u2019s disease","volume":"31","author":"Bezprozvanny","year":"2008","journal-title":"Trends Neurosci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.molmed.2009.01.001","article-title":"Calcium signaling and neurodegenerative diseases","volume":"15","author":"Bezprozvanny","year":"2009","journal-title":"Trends Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4161\/pri.21767","article-title":"Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia","volume":"7","author":"Berridge","year":"2013","journal-title":"Prion"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1155","article-title":"Calcium signalling: Dynamics, homeostasis and remodelling","volume":"4","author":"Berridge","year":"2003","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6701324","DOI":"10.1155\/2016\/6701324","article-title":"Intracellular Calcium Dysregulation: Implications for Alzheimer\u2019s Disease","volume":"2016","author":"Magi","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1242\/jcs.117135","article-title":"CALHM1 controls the Ca(2)(+)-dependent MEK, ERK, RSK and MSK signaling cascade in neurons","volume":"126","author":"Vingtdeux","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"24250","DOI":"10.1038\/srep24250","article-title":"CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice","volume":"6","author":"Vingtdeux","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2174\/156720508786898451","article-title":"Oxidative stress signaling in Alzheimer\u2019s disease","volume":"5","author":"Su","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/156720506778249489","article-title":"Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer\u2019s disease","volume":"3","author":"Onyango","year":"2006","journal-title":"Curr. Alzheimer Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liao, Y., Dong, Y., and Cheng, J. (2017). The Function of the Mitochondrial Calcium Uniporter in Neurodegenerative Disorders. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020248"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"20158","DOI":"10.1038\/srep20158","article-title":"Amplified RLR signaling activation through an interferon-stimulated gene-endoplasmic reticulum stress-mitochondrial calcium uniporter protein loop","volume":"6","author":"Cheng","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s13238-015-0144-6","article-title":"Mitochondrial calcium uniporter protein MCU is involved in oxidative stress-induced cell death","volume":"6","author":"Liao","year":"2015","journal-title":"Protein Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer\u2019s disease: A review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1755-5949.2010.00175.x","article-title":"Beyond the cholinergic hypothesis: Do current drugs work in Alzheimer\u2019s disease?","volume":"16","author":"Martorana","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.npep.2015.06.008","article-title":"Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer\u2019s disease","volume":"52","author":"Barage","year":"2015","journal-title":"Neuropeptides"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer\u2019s disease: An appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nature Rev. Drug Discov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","article-title":"Alzheimer\u2019s disease: Genes, proteins, and therapy","volume":"81","author":"Selkoe","year":"2001","journal-title":"Physiol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.emboj.7600061","article-title":"Take five\u2013BACE and the gamma-secretase quartet conduct Alzheimer\u2019s amyloid beta-peptide generation","volume":"23","author":"Haass","year":"2004","journal-title":"EMBO J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: Enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"Vassar","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.274.5284.99","article-title":"Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice","volume":"274","author":"Hsiao","year":"1996","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0006-8993(02)03476-5","article-title":"Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation","volume":"956","author":"Lalonde","year":"2002","journal-title":"Brain Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","article-title":"ApoE promotes the proteolytic degradation of Abeta","volume":"58","author":"Jiang","year":"2008","journal-title":"Neuron"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2174\/15672050113109990156","article-title":"Impact of apolipoprotein E on Alzheimer\u2019s disease","volume":"10","author":"Hauser","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3233\/JAD-2010-100948","article-title":"Amyloid-beta induces caspase-dependent loss of PSD-95 and synaptophysin through NMDA receptors","volume":"22","author":"Liu","year":"2010","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer\u2019s disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/pri.22118","article-title":"Alzheimer disease: A tale of two prions","volume":"7","author":"Nussbaum","year":"2013","journal-title":"Prion"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0896-6273(00)80230-5","article-title":"Familial Alzheimer\u2019s disease-linked presenilin 1 variants elevate Abeta1-42\/1-40 ratio in vitro and in vivo","volume":"17","author":"Borchelt","year":"1996","journal-title":"Neuron"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12035-012-8251-3","article-title":"Abeta toxicity in Alzheimer\u2019s disease","volume":"45","author":"Cavallucci","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","article-title":"Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer\u2019s disease","volume":"27","author":"Lacor","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/nature07767","article-title":"APP binds DR6 to trigger axon pruning and neuron death via distinct caspases","volume":"457","author":"Nikolaev","year":"2009","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: The amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jalz.2007.11.008","article-title":"The amyloid cascade hypothesis","volume":"4","author":"Korczyn","year":"2008","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X15666170116143743","article-title":"The amyloid cascade hypothesis in Alzheimer\u2019s disease: It\u2019s time to change our mind","volume":"15","author":"Ricciarelli","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2047-9158-1-18","article-title":"Advances in the pathogenesis of Alzheimer\u2019s disease: A re-evaluation of amyloid cascade hypothesis","volume":"1","author":"Dong","year":"2012","journal-title":"Transl. Neurodegener."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"(2011). The amyloid cascade hypothesis has misled the pharmaceutical industry. Biochem. Soc. Trans., 39, 920\u2013923.","DOI":"10.1042\/BST0390920"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1750-3639.1991.tb00671.x","article-title":"Tau proteins and neurofibrillary degeneration","volume":"1","author":"Goedert","year":"1991","journal-title":"Brain Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0188-4409(01)00316-2","article-title":"The molecular bases of Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"32","author":"Maccioni","year":"2001","journal-title":"Arch. Med. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","article-title":"Tau pathology in Alzheimer disease and other tauopathies","volume":"1739","author":"Iqbal","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2741\/2097","article-title":"The role of tau phosphorylation and cleavage in neuronal cell death","volume":"12","author":"Chun","year":"2007","journal-title":"Front. Biosci. J. Virtual Libr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/nprot.2006.327","article-title":"Isolation of murine microglial cells for RNA analysis or flow cytometry","volume":"1","author":"Cardona","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.brainres.2014.07.050","article-title":"Interactions of innate and adaptive immunity in brain development and function","volume":"1617","author":"Filiano","year":"2015","journal-title":"Brain Res."},{"key":"ref_68","first-page":"519","article-title":"Microglia\u2014Insights into immune system structure, function, and reactivity in the central nervous system","volume":"26","author":"Wirenfeldt","year":"2011","journal-title":"Histol. Histopathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/glia.1106","article-title":"Immune function of microglia","volume":"36","author":"Aloisi","year":"2001","journal-title":"Glia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1152\/physrev.00011.2010","article-title":"Physiology of microglia","volume":"91","author":"Kettenmann","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Ji, K., Akgul, G., Wollmuth, L.P., and Tsirka, S.E. (2013). Microglia actively regulate the number of functional synapses. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056293"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.cell.2013.11.030","article-title":"Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor","volume":"155","author":"Parkhurst","year":"2013","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A Unique Microglia Type Associated with Restricting Development of Alzheimer\u2019s Disease","volume":"169","author":"Spinrad","year":"2017","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/glia.20468","article-title":"Microglia derived from aging mice exhibit an altered inflammatory profile","volume":"55","author":"Sierra","year":"2007","journal-title":"Glia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fncel.2013.00022","article-title":"Microglial aging in the healthy CNS: Phenotypes, drivers, and rejuvenation","volume":"7","author":"Wong","year":"2013","journal-title":"Front. Cell. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/glia.20678","article-title":"Microglial dystrophy in the aged and Alzheimer\u2019s disease brain is associated with ferritin immunoreactivity","volume":"56","author":"Lopes","year":"2008","journal-title":"Glia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cmet.2013.09.010","article-title":"Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging","volume":"18","author":"Youm","year":"2013","journal-title":"Cell Metabol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tins.2006.07.001","article-title":"Microglial senescence: Does the brain\u2019s immune system have an expiration date?","volume":"29","author":"Streit","year":"2006","journal-title":"Trends Neurosci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-2094-2-9","article-title":"Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer\u2019s disease","volume":"2","author":"Patel","year":"2005","journal-title":"J. Neuroinflammation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0002-9440(10)65542-3","article-title":"Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer\u2019s disease brains","volume":"153","author":"Xia","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1440-1819.1997.tb02375.x","article-title":"Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer\u2019s disease","volume":"51","author":"Ishizuka","year":"1997","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ni.1836","article-title":"CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer","volume":"11","author":"Stewart","year":"2010","journal-title":"Nature Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1523\/JNEUROSCI.23-07-02665.2003","article-title":"A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation","volume":"23","author":"Bamberger","year":"2003","journal-title":"J. Neurosci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1096\/fj.03-0364fje","article-title":"The LPS receptor (CD14) links innate immunity with Alzheimer\u2019s disease","volume":"18","author":"Fassbender","year":"2004","journal-title":"FASEB J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1084\/jem.20021546","article-title":"CD36 mediates the innate host response to beta-amyloid","volume":"197","author":"Moore","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/ni.2668","article-title":"NLRP3 inflammasome activation: CD36 serves double duty","volume":"14","author":"Kagan","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/ni.2639","article-title":"CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation","volume":"14","author":"Sheedy","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-016-0088-1","article-title":"The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer\u2019s disease","volume":"11","author":"Saresella","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature11729","article-title":"NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice","volume":"493","author":"Heneka","year":"2013","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nn.3435","article-title":"CD33 Alzheimer\u2019s disease locus: Altered monocyte function and amyloid biology","volume":"16","author":"Bradshaw","year":"2013","journal-title":"Nat. Neurosci."},{"key":"ref_92","first-page":"E1589","article-title":"Alzheimer\u2019s disease CD33 rs3865444 variant does not contribute to cognitive performance","volume":"113","author":"Liu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.neuron.2013.04.014","article-title":"Alzheimer\u2019s disease risk gene CD33 inhibits microglial uptake of amyloid beta","volume":"78","author":"Griciuc","year":"2013","journal-title":"Neuron"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","article-title":"Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer\u2019s disease mice","volume":"28","author":"Hickman","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS beta-amyloid in Alzheimer\u2019s disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.immuni.2014.01.006","article-title":"Transcriptome-based network analysis reveals a spectrum model of human macrophage activation","volume":"40","author":"Xue","year":"2014","journal-title":"Immunity"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nn.4338","article-title":"A polarizing question: Do M1 and M2 microglia exist?","volume":"19","author":"Ransohoff","year":"2016","journal-title":"Nat. Neurosci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bph.13139","article-title":"Microglial M1\/M2 polarization and metabolic states","volume":"173","author":"Orihuela","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1523\/JNEUROSCI.18-06-02161.1998","article-title":"Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo","volume":"18","author":"Weldon","year":"1998","journal-title":"J. Neurosci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"8240","DOI":"10.1523\/JNEUROSCI.1808-05.2005","article-title":"Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines","volume":"25","author":"Landreth","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.4049\/jimmunol.181.6.3877","article-title":"Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes","volume":"181","author":"Yamamoto","year":"2008","journal-title":"J. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2009.02.003","article-title":"Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta","volume":"210","author":"Michelucci","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbi.2016.12.014","article-title":"Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP\/PS1 mice","volume":"61","author":"Dempsey","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1038\/s41467-018-06449-x","article-title":"Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer\u2019s disease mouse model","volume":"9","author":"Flores","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jneuroim.2013.10.002","article-title":"NLRP3 polymorphisms are associated with late-onset Alzheimer\u2019s disease in Han Chinese","volume":"265","author":"Tan","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s12035-013-8475-x","article-title":"The NLRP3 inflammasome in Alzheimer\u2019s disease","volume":"48","author":"Tan","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/106002809402800612","article-title":"Tacrine: First drug approved for Alzheimer\u2019s disease","volume":"28","author":"Crismon","year":"1994","journal-title":"Ann. Pharmacother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1742-7843.2011.00677.x","article-title":"Tacrine treatment at high dose suppresses the recognition memory in juvenile and adult mice with attention to hepatotoxicity","volume":"108","author":"Pan","year":"2011","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_109","first-page":"160","article-title":"Hepatotoxicity of tacrine: Occurrence of membrane fluidity alterations without involvement of lipid peroxidation","volume":"294","author":"Galisteo","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-2002-19833","article-title":"Safety and efficacy of idebenone versus tacrine in patients with Alzheimer\u2019s disease: Results of a randomized, double-blind, parallel-group multicenter study","volume":"35","author":"Gutzmann","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00002093-199806000-00007","article-title":"Safety of tacrine: Clinical trials, treatment IND, and postmarketing experience","volume":"12","author":"Gracon","year":"1998","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1185\/030079905X65402","article-title":"Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: Review of neuropsychiatric impairment in Alzheimer\u2019s disease","volume":"21","author":"Grossberg","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: International randomised controlled trial","volume":"318","author":"Rosler","year":"1999","journal-title":"BMJ"},{"key":"ref_114","first-page":"CD001747","article-title":"Galantamine for Alzheimer\u2019s disease","volume":"3","author":"Olin","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1468-1331.2004.00885.x","article-title":"Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer\u2019s disease: Multicenter trial","volume":"11","author":"Pirttila","year":"2004","journal-title":"Eur. J. Neurol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1586\/14737175.7.10.1243","article-title":"Donepezil for Alzheimer\u2019s disease","volume":"7","author":"Benjamin","year":"2007","journal-title":"Expert Rev. Neurother."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","article-title":"Donepezil in patients with severe Alzheimer\u2019s disease: Double-blind, parallel-group, placebo-controlled study","volume":"367","author":"Winblad","year":"2006","journal-title":"Lancet"},{"key":"ref_118","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"1","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Ali, T.B., Schleret, T.R., Reilly, B.M., Chen, W.Y., and Abagyan, R. (2015). Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144337"},{"key":"ref_120","unstructured":"Inglis, F. (2002). The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int. J. Clin. Pract. Suppl., 45\u201363."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM200308073490616","article-title":"Memantine in moderate-to-severe Alzheimer\u2019s disease","volume":"349","author":"Bleich","year":"2003","journal-title":"New Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archneurol.2011.69","article-title":"Lack of evidence for the efficacy of memantine in mild Alzheimer disease","volume":"68","author":"Schneider","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1203475416659858","article-title":"Acitretin","volume":"21","author":"Tan","year":"2017","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1177\/1203475417733414","article-title":"Acitretin Use in Dermatology","volume":"21","author":"Guenther","year":"2017","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17425255.2018.1515198","article-title":"Pharmacokinetics of tazarotene and acitretin in psoriasis","volume":"14","author":"Heath","year":"2018","journal-title":"Expert Opin. Drug Metabol. Toxicol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","article-title":"Increased CSF APPs-alpha levels in patients with Alzheimer disease treated with acitretin","volume":"83","author":"Endres","year":"2014","journal-title":"Neurology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1389450116666150825113655","article-title":"Potential Role of (\u2212)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease","volume":"18","author":"Xicota","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12937-016-0179-4","article-title":"Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)","volume":"15","author":"Singh","year":"2016","journal-title":"Nutr. J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuropharm.2012.11.009","article-title":"Etazolate, an alpha-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice","volume":"67","author":"Siopi","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","article-title":"Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing","volume":"106","author":"Marcade","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3233\/JAD-160701","article-title":"AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer\u2019s Disease","volume":"55","author":"Cebers","year":"2017","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3233\/JAD-150834","article-title":"AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics","volume":"50","author":"Eketjall","year":"2016","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/S0140-6736(18)31425-9","article-title":"Alzheimer\u2019s disease research: The future of BACE inhibitors","volume":"391","author":"Burki","year":"2018","journal-title":"Lancet"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fnagi.2018.00229","article-title":"BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines","volume":"10","author":"Blume","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1021\/acs.orglett.8b00259","article-title":"A Next Generation Synthesis of BACE1 Inhibitor Verubecestat (MK-8931)","volume":"20","author":"Thaisrivongs","year":"2018","journal-title":"Org. Lett."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"10435","DOI":"10.1021\/acs.jmedchem.6b00307","article-title":"Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer\u2019s Disease","volume":"59","author":"Scott","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in Alzheimer\u2019s disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13195-018-0415-6","article-title":"Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer\u2019s disease: Randomized, double-blind, placebo-controlled study","volume":"10","author":"Timmers","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/jcph.1087","article-title":"Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis","volume":"58","author":"Timmers","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.trci.2016.08.001","article-title":"Profiling the dynamics of CSF and plasma Abeta reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor","volume":"2","author":"Timmers","year":"2016","journal-title":"Alzheimers Dement. (N. Y.)"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e9316","DOI":"10.15252\/emmm.201809316","article-title":"The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer\u2019s disease","volume":"10","author":"Neumann","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_142","first-page":"242","article-title":"The Alzheimer\u2019s Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer\u2019s Disease","volume":"4","author":"Caputo","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"8501693","DOI":"10.1155\/2016\/8501693","article-title":"Current Research Therapeutic Strategies for Alzheimer\u2019s Disease Treatment","volume":"2016","author":"Folch","year":"2016","journal-title":"Neural Plast."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40262-012-0005-x","article-title":"A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects","volume":"51","author":"Dockens","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40261-012-0006-4","article-title":"Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Abeta levels in healthy young men","volume":"32","author":"Tong","year":"2012","journal-title":"Clin. Drug Investig."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1073\/pnas.1402228111","article-title":"Clioquinol promotes the degradation of metal-dependent amyloid-beta (Abeta) oligomers to restore endocytosis and ameliorate Abeta toxicity","volume":"111","author":"Matlack","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/cpdd.14","article-title":"Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects","volume":"2","author":"Liang","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/BF03654836","article-title":"The potential protective effect of tramiprosate (homotaurine) against Alzheimer\u2019s disease: A review","volume":"24","author":"Caltagirone","year":"2012","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease\u2014A randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci. AMS"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","article-title":"Effect of tramiprosate in patients with mild-to-moderate Alzheimer\u2019s disease: Exploratory analyses of the MRI sub-group of the Alphase study","volume":"13","author":"Gauthier","year":"2009","journal-title":"J. Nutr. Health Aging"},{"key":"ref_154","first-page":"136","article-title":"Clinical Effects of Oral Tramiprosate in APOE4\/4 Homozygous Patients with Mild Alzheimer\u2019s Disease Suggest Disease Modification","volume":"4","author":"Sabbagh","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","article-title":"Elucidating the Abeta42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer\u2019s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data","volume":"31","author":"Kocis","year":"2017","journal-title":"CNS Drugs"},{"key":"ref_156","first-page":"149","article-title":"Clinical Effects of Tramiprosate in APOE4\/4 Homozygous Patients with Mild Alzheimer\u2019s Disease Suggest Disease Modification Potential","volume":"4","author":"Abushakra","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_157","first-page":"219","article-title":"Clinical Benefits of Tramiprosate in Alzheimer\u2019s Disease Are Associated with Higher Number of APOE4 Alleles: The \u201cAPOE4 Gene-Dose Effect\u201d","volume":"3","author":"Abushakra","year":"2016","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1021\/acschemneuro.7b00439","article-title":"Synergistic Inhibitory Effect of GQDs-Tramiprosate Covalent Binding on Amyloid Aggregation","volume":"9","author":"Liu","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer\u2019s Disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","article-title":"Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain","volume":"32","author":"Hey","year":"2018","journal-title":"CNS Drugs"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","article-title":"Alzheimer\u2019s disease drug development pipeline: 2018","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimers Dement. (N. Y.)"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: Follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2174\/1567205014666170117101537","article-title":"Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer\u2019s Disease","volume":"14","author":"Hull","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer\u2019s Disease","volume":"51","author":"Pasquier","year":"2016","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_166","first-page":"75","article-title":"Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer\u2019s Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study","volume":"3","author":"Sadowsky","year":"2016","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1517\/14712598.2013.789856","article-title":"Bapineuzumab and solanezumab for Alzheimer\u2019s disease: Is the \u2018amyloid cascade hypothesis\u2019 still alive?","volume":"13","author":"Tayeb","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jmb.2011.11.047","article-title":"Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer\u2019s disease","volume":"421","author":"Bollini","year":"2012","journal-title":"J. Mol. Biol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e31827db49b","article-title":"Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: A phase I, randomized, placebo-controlled, double-blind, dose-escalation study","volume":"36","author":"Landen","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trci.2017.04.003","article-title":"Multiple-dose ponezumab for mild-to-moderate Alzheimer\u2019s disease: Safety and efficacy","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement. (N. Y.)"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.trci.2017.05.003","article-title":"Ponezumab in mild-to-moderate Alzheimer\u2019s disease: Randomized phase II PET-PIB study","volume":"3","author":"Landen","year":"2017","journal-title":"Alzheimers Dement. (N. Y.)"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Andreasen, N., Simeoni, M., Ostlund, H., Lisjo, P.I., Fladby, T., Loercher, A.E., Byrne, G.J., Murray, F., Scott-Stevens, P.T., and Wallin, A. (2015). First administration of the Fc-attenuated anti-beta amyloid antibody GSK933776 to patients with mild Alzheimer\u2019s disease: A randomized, placebo-controlled study. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0098153"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/alzrt249","article-title":"Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer\u2019s disease: A phase I study","volume":"6","author":"Leyhe","year":"2014","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.trci.2016.06.002","article-title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement. (N. Y.)"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1523\/JNEUROSCI.0420-17.2017","article-title":"Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer\u2019s Disease","volume":"37","author":"Gamage","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"12549","DOI":"10.1523\/JNEUROSCI.2080-16.2016","article-title":"Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice","volume":"36","author":"Kastanenka","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_179","first-page":"255","article-title":"Clinical Development of Aducanumab, an Anti-Abeta Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer\u2019s Disease","volume":"4","author":"Chiao","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Chiao, P., Bedell, B.J., Avants, B., Zijdenbos, A.P., Grand\u2019Maison, M., O\u2019Neill, P., O\u2019Gorman, J., Chen, T., and Koeppe, R. (2018). Impact of Reference\/Target Region Selection on Amyloid PET Standard Uptake Value Ratios in the Phase 1b PRIME Study of Aducanumab. J. Nucl. Med.","DOI":"10.2967\/jnumed.118.209130"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"39374","DOI":"10.1038\/srep39374","article-title":"Structure of Crenezumab Complex with Abeta Shows Loss of beta-Hairpin","volume":"6","author":"Ultsch","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1517\/14712598.2012.688022","article-title":"Gantenerumab for the treatment of Alzheimer\u2019s disease","volume":"12","author":"Delrieu","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_188","first-page":"1359","article-title":"Profile of gantenerumab and its potential in the treatment of Alzheimer\u2019s disease","volume":"7","author":"Novakovic","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer\u2019s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial","volume":"61","author":"Wilcock","year":"2018","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_194","first-page":"236","article-title":"Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer\u2019s Disease and Other Tauopathies","volume":"4","author":"West","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/alzrt278","article-title":"First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model","volume":"6","author":"Kontsekova","year":"2014","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13195-018-0436-1","article-title":"FUNDAMANT: An interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer\u2019s disease","volume":"10","author":"Novak","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","article-title":"Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Novak","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-12-0061","article-title":"TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells","volume":"11","author":"Fitzgerald","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bmj.327.7407.128","article-title":"Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer\u2019s disease: Systematic review and meta-analysis of observational studies","volume":"327","author":"Etminan","year":"2003","journal-title":"BMJ"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1212\/WNL.0b013e3181a18691","article-title":"Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort","volume":"72","author":"Breitner","year":"2009","journal-title":"Neurology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1212\/01.wnl.0000311269.57716.63","article-title":"Protective effects of NSAIDs on the development of Alzheimer disease","volume":"70","author":"Vlad","year":"2008","journal-title":"Neurology"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMoa010178","article-title":"Nonsteroidal antiinflammatory drugs and the risk of Alzheimer\u2019s disease","volume":"345","author":"Ruitenberg","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"12504","DOI":"10.1038\/ncomms12504","article-title":"Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer\u2019s disease in rodent models","volume":"7","author":"Daniels","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-141506","article-title":"Anti-inflammatory drugs and risk of Alzheimer\u2019s disease: An updated systematic review and meta-analysis","volume":"44","author":"Wang","year":"2015","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40266-015-0239-z","article-title":"Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer\u2019s disease: A systematic review and meta-analysis of treatment effect","volume":"32","author":"Garatachea","year":"2015","journal-title":"Drugs Aging"},{"key":"ref_207","first-page":"CD006378","article-title":"Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease","volume":"2","author":"Jaturapatporn","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF03325217","article-title":"A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer\u2019s disease","volume":"21","author":"Pasqualetti","year":"2009","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejps.2016.05.012","article-title":"Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer\u2019s disease","volume":"92","author":"Muntimadugu","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","article-title":"Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial","volume":"84","author":"Butchart","year":"2015","journal-title":"Neurology"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1021\/ml2001455","article-title":"The Discovery of VX-745: A Novel and Selective p38alpha Kinase Inhibitor","volume":"2","author":"Duffy","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_214","first-page":"273","article-title":"Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38alpha to Reverse Synaptic Dysfunction in Early Alzheimer\u2019s Disease","volume":"4","author":"Alam","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_215","first-page":"149","article-title":"Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer\u2019s Disease","volume":"5","author":"Burstein","year":"2018","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Burstein, A.H., Grimes, I., Galasko, D.R., Aisen, P.S., Sabbagh, M., and Mjalli, A.M. (2014). Effect of TTP488 in patients with mild to moderate Alzheimer\u2019s disease. BMC Neurol., 14.","DOI":"10.1186\/1471-2377-14-12"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13543784.2017.1265504","article-title":"Pioglitazone for the treatment of Alzheimer\u2019s disease","volume":"26","author":"Galimberti","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archneurol.2010.229","article-title":"A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease","volume":"68","author":"Geldmacher","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","article-title":"Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease","volume":"32","author":"Sato","year":"2011","journal-title":"Neurobiol. Aging"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/3\/558\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:29:15Z","timestamp":1760185755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/3\/558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":219,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["ijms20030558"],"URL":"https:\/\/doi.org\/10.3390\/ijms20030558","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]}}}